Journey Medical Corporation (DERM)
DERM Stock Price Chart
Explore Journey Medical Corporation interactive price chart. Choose custom timeframes to analyze DERM price movements and trends.
DERM Company Profile
Discover essential business fundamentals and corporate details for Journey Medical Corporation (DERM) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
12 Nov 2021
Employees
41.00
Website
https://journeymedicalcorp.comCEO
Claude Maraoui
Description
Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.
DERM Financial Timeline
Browse a chronological timeline of Journey Medical Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.01, while revenue estimate is $18.36m.
Earnings released on 13 May 2026
EPS came in at -$0.08 falling short of the estimated -$0.07 by -14.29%, while revenue for the quarter reached $15.96m , beating expectations by +3.16%.
Earnings released on 25 Mar 2026
EPS came in at -$0.04 surpassing the estimated -$0.06 by +33.33%, while revenue for the quarter reached $16.08m , missing expectations by -14.71%.
Earnings released on 12 Nov 2025
EPS came in at -$0.09 falling short of the estimated -$0.08 by -12.50%, while revenue for the quarter reached $17.63m , missing expectations by -6.53%.
Earnings released on 12 Aug 2025
EPS came in at -$0.16 falling short of the estimated -$0.07 by -128.57%, while revenue for the quarter reached $15.01m , missing expectations by -20.60%.
Earnings released on 14 May 2025
EPS came in at -$0.18 surpassing the estimated -$0.24 by +25.00%, while revenue for the quarter reached $13.14m , missing expectations by -12.01%.
Earnings released on 26 Mar 2025
EPS came in at $0.08 surpassing the estimated -$0.22 by +136.36%, while revenue for the quarter reached $13.62m , beating expectations by +12.99%.
Earnings released on 12 Nov 2024
EPS came in at -$0.12 surpassing the estimated -$0.17 by +29.41%, while revenue for the quarter reached $14.63m , beating expectations by +2.93%.
Earnings released on 12 Aug 2024
EPS came in at -$0.17 falling short of the estimated -$0.15 by -13.33%, while revenue for the quarter reached $14.86m , beating expectations by +3.23%.
Earnings released on 13 May 2024
EPS came in at -$0.53 falling short of the estimated -$0.26 by -103.85%, while revenue for the quarter reached $13.03m , missing expectations by -7.62%.
Earnings released on 21 Mar 2024
EPS came in at -$0.12 falling short of the estimated -$0.08 by -50.00%, while revenue for the quarter reached $15.26m , beating expectations by +1.31%.
Earnings released on 7 Nov 2023
EPS came in at $0.80 surpassing the estimated -$0.15 by +633.33%, while revenue for the quarter reached $34.54m , beating expectations by +122.40%.
Earnings released on 8 Aug 2023
EPS came in at -$0.46 falling short of the estimated -$0.34 by -35.29%, while revenue for the quarter reached $17.17m , beating expectations by +13.27%.
Earnings released on 22 May 2023
EPS came in at -$0.57 falling short of the estimated -$0.44 by -29.55%, while revenue for the quarter reached $12.21m , missing expectations by -18.96%.
Earnings released on 29 Mar 2023
EPS came in at -$0.60 falling short of the estimated -$0.37 by -62.16%, while revenue for the quarter reached $15.97m , missing expectations by -1.32%.
Earnings released on 10 Nov 2022
EPS came in at -$0.57 falling short of the estimated -$0.34 by -67.65%, while revenue for the quarter reached $16.12m , missing expectations by -2.80%.
Earnings released on 9 Aug 2022
EPS came in at -$0.43 falling short of the estimated -$0.25 by -72.00%, while revenue for the quarter reached $18.29m , missing expectations by -14.13%.
Earnings released on 10 May 2022
EPS came in at -$0.08 surpassing the estimated -$0.18 by +55.56%, while revenue for the quarter reached $23.30m , beating expectations by +5.11%.
Earnings released on 23 Mar 2022
EPS came in at -$1.64 falling short of the estimated -$0.29 by -465.52%, while revenue for the quarter reached $17.52m , missing expectations by -14.08%.
Earnings released on 10 Dec 2021
EPS came in at -$1.16 falling short of the estimated -$0.87 by -33.57%, while revenue for the quarter reached $19.61m , beating expectations by +46.89%.
Earnings released on 12 Nov 2021
EPS came in at -$1.30 , while revenue for the quarter reached $15.29m .
DERM Stock Performance
Access detailed DERM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
